Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Effect of cTBS on Startle and TMS-evoked BOLD

NCT: NCT07415772 · NOT_YET_RECRUITING

NCT IDNCT07415772
StatusNOT_YET_RECRUITING
Start Date2026-09-01
Completion2031-06-30
SponsorUniversity of Pennsylvania (OTHER)
First posted
Last updated

Brief Summary

The right dorsolateral prefrontal cortex (dlPFC) is increasingly being targeted with transcranial magnetic stimulation (TMS) to reduce anxiety expression; however, there is little mechanistic evidence supporting an optimized treatment protocol. Thus, the objective of the current project is to develop an interleaved TMS/fMRI that can assess the effect of neuromodulatory (potentially therapeutic) TMS protocols on neural and behavioral measures related to anxiety expression. PUBLIC HEALTH RELEVANCE: These results will yield direct evidence that 1 Hz and cTBS modulate brain activity associated with anxiety expression and regulation, thus informing novel TMS based anxiety treatments.

Frequently Asked Questions

What is Effect of cTBS on Startle and TMS-evoked BOLD?

Effect of cTBS on Startle and TMS-evoked BOLD is a clinical trial registered under NCT07415772. Current status: NOT_YET_RECRUITING.

What is the status of NCT07415772?

The current status of NCT07415772 (Effect of cTBS on Startle and TMS-evoked BOLD) is: NOT_YET_RECRUITING.

When did Effect of cTBS on Startle and TMS-evoked BOLD start?

Effect of cTBS on Startle and TMS-evoked BOLD started on 2026-09-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.